Evidence map›Paper›PMID 40616739›Full record

ArticleJournal of computer-aided molecular design2025

3CL

Muzaffar Kayumov, Jamoliddin Razzokov, Mukhriddin Makhkamov, Murodjon Radjabov, Nurkhodja Mukhamedov, Makhmudjon Khakimov, Akmal M Asrorov, Okhunjon Khasanov, Ansor Yashinov, Mugrajitdin Tashmukhamedov and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Muzaffar KayumovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, Uzbekistan. mqayumov0808@gmail.com.
Jamoliddin RazzokovInstitute of Fundamental and Applied Research, National Research University TIIAME, Kori Niyoziy 39, Tashkent, 100000, Uzbekistan.
Mukhriddin MakhkamovTashkent International University of Education, Imom Bukhoriy 6, Tashkent, 100207, Uzbekistan.
Murodjon RadjabovDepartment of Natural Compounds and Applied Chemistry, National University of Uzbekistan, Universitet 4, Tashkent, 100174, Uzbekistan.
Nurkhodja MukhamedovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, Uzbekistan.
Makhmudjon KhakimovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, Uzbekistan.
Akmal M AsrorovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, Uzbekistan.
Okhunjon KhasanovDepartment of Medical Biological Sciences, Kimyo International University, Shota Rustaveli 156, Tashkent, 100121, Uzbekistan.
Ansor YashinovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, Uzbekistan.
Mugrajitdin TashmukhamedovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, Uzbekistan.
Ahmidin WaliXinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing Road 40-1, Urumqi, 830011, China.
Abulimiti YiliXinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing Road 40-1, Urumqi, 830011, China.
Sharafitdin MirzaakhmedovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, Uzbekistan.

Funding

CAS, PIFI fund 2024VBA0019Ministry of Innovative Development of the Republic of Uzbekistan F-FA-2021-359
6 · The paper itself

Abstract

The rapid spread of SARS-CoV-2 and its widespread public health implications have highlighted the urgent need for effective antiviral therapies. A promising strategy is to investigate natural compounds that may inhibit the key viral targets. In this work, we demonstrated the anti-SARS-CoV-2 activity of six bufadienolides, including bufalin (A), arenobufagin (B), gamabufotalin (C), telocinobufagin (D), marinobufagin (E), and bufarenogin (F) from the venom of the Central Asian green toad, Bufo viridis. Molecular docking assays revealed that all A-F bufadienolides bind to key residues (Thr26, His41, Met49, Met161, and Gln189) in the catalytic pocket of 3-chymotrypsin-like cysteine protease (3CL

Indexed as

Antiviral AgentsBufanolidesCoronavirus 3C ProteasesCOVID-19 Drug TreatmentSARS-CoV-2AnimalsCOVID-19HumansMolecular Docking SimulationMolecular Dynamics Simulation3C-like proteinase, SARS-CoV-2Antiviral AgentsBufanolidesCoronavirus 3C Proteases3CLproBufadienolidesComputer simulationsIn vitro analysisMolecular dynamicsUmbrella sampling

Identifiers

PMID40616739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.